MNV
Market News Video
MNV MNV 10 Oversold Stocks You Need To Know About
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Notable Thursday Option Activity: CMG, FNKO, CYTK
Thursday, December 28, 4:01 PM ET, by Market News Video Staff

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...

SPDR S&P Biotech ETF Experiences Big Outflow
Tuesday, January 2, 12:23 PM ET, by Market News Video Staff

Symbols mentioned in this story: XBI, KRTX, ACAD, CYTK Exchange traded funds (ETFs) trade just ...

February 23rd Options Now Available For Cytokinetics (CYTK)
Thursday, January 4, 11:40 AM ET, by Market News Video Staff

Investors in Cytokinetics Inc (CYTK) saw new options become available today, for the February 23rd ...

Notable ETF Inflow Detected - IWM, MSTR, SSD, CYTK
Wednesday, January 10, 10:50 AM ET, by Market News Video Staff

Symbols mentioned in this story: IWM, MSTR, SSD, CYTK Exchange traded funds (ETFs) trade just ...

Notable Tuesday Option Activity: AMPY, CYTK, PRGS
Tuesday, January 16, 5:24 PM ET, by Market News Video Staff

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...

Investors Land CYTK Even Cheaper Than Its Secondary Stock Offering

By Market News Video Staff, Tuesday, July 27, 11:37 AM ET
Play Video: The Importance of ETFs


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Email EnvelopeFree Email Alerts By Stock:
Get Dividend Alerts
Get SEC Filing Alerts

Looking back to 7 days ago, Cytokinetics Inc (NASDAQ:CYTK) priced a 10,000,000 share secondary stock offering at $27.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time. In trading on Tuesday, bargain hunters could buy shares of CYTK and achieve a cost basis 1.5% cheaper than those buyers, with shares changing hands as low as $27.10 per share.

Secondaries can often present buying opportunities for bullish investors interested in purchasing shares, because the sudden extra supply of stock tends to require that the offering be priced at an attractive discount to where the stock had previously been trading before the offering announcement. At last check, Cytokinetics Inc shares are currently trading down about 3.9% on the day. The chart below shows the one year performance of CYTK shares, versus its 200 day moving average:

Cytokinetics Inc Chart

Looking at the chart above, CYTK's low point in its 52 week range is $14.71 per share, with $31.41 as the 52 week high point — that compares with a last trade of $27.07.


Special Offer: Join the income investing conversation on ValueForum.com with a special Seven Days for Seven Dollars invitation.


This Article's Word Cloud:   Buyers   CYTK   Cytokinetics   Days   Dollars   Join   Looking   Offer   Offerings   Recent   Secondaries   Secondary   Seven   Special   Start   Stock   Tuesday   ValueForum   about   above   achieve   announcement   attractive   average   back   bargain   basis   because   been   before   below   bullish   buyers   buying   changing   chart   cheaper   check   investment   last   offering   point   priced   share   shares   stock   that   trading   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Investors Land CYTK Even Cheaper Than Its Secondary Stock Offering | Market News Video | Copyright © 2008 - 2024, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.

X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.